title: Concentration of soluble CD4, CD8 and CD25 receptors in early localized and early disseminated Lyme borreliosis.
abstract: BACKGROUND
  The aim of this study was to evaluate the concentrations of soluble CD4, CD8 and CD25 antigens in the serum of patients with early LocaLized, (group I, n = 22 patients) and early disseminated Lyme borreliosis (group II n = 23 patients), before and after antibiotic therapy compared with controls (group III n = 7 healthy persons).
  
  
  METHODS
  The diagnosis of Lyme borreliosis based on clinical features was confirmed by ELISA and Western blot. The assays of sCD4, sCD8 and sCD25 concentrations were performed using Endogen (USA) kits.
  
  
  RESULTS
  In group I the sCD4 level decreased in examination 2 (p < 0.001) compared to examination 1. The mean concentration of sCD8 in initial examination 1 in group II was higher than in controls (p < 0.0001); it decreased in examination 2 but was still higher (p < 0.01) than in controls (p < 0.006). Prior to treatment mean sCD25 concentration in group II was higher compared to controls (p < 0.0008) like in examination 2 after treatment (p < 0.02) and this persisted. The mean value of sCD8 in initial examination 1 before treatment in group II was higher than in group I (p < 0.00001).
  
  
  CONCLUSIONS
  Increased initial concentrations of sCD8 and sCD25 indicate the activation of CD8 and CD25 lymphocytes and their role in immunopathogenesis of Lyme disease. Elevated levels of sCD8 in group II before and after treatment suggest a significant involvement of CD8 lymphocytes, indicating the role of long-lasting cellular response in this stage of Lyme disease.
authors.affiliation: Dept of Infectious Diseases and Neuroinfectious, Medical Academy of Bialystok, Poland. Zajkowsk@kki.net.pl
authors.forename: J
authors.initials: J
authors.lastname: Zajkowska
authors.forename: T
authors.initials: T
authors.lastname: Hermanowska-Szpakowicz
authors.forename: R
authors.initials: R
authors.lastname: Swierzbinska
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D015153:Blotting, Western; D015704:CD4 Antigens / Q000032:analysis* / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D018450:Disease Progression; D006801:Humans; D008193:Lyme Disease / Q000188:drug therapy / Q000276:immunology*; D011948:Receptors, Antigen, T-Cell / Q000032:analysis* / Q000276:immunology; D015375:Receptors, Interleukin-2 / Q000032:analysis* / Q000276:immunology; D012720:Severity of Illness Index
chemical_list: D000900:Anti-Bacterial Agents; D015704:CD4 Antigens; C067361:CD8 receptor; D011948:Receptors, Antigen, T-Cell; D015375:Receptors, Interleukin-2